A risky business: recalibrating the future of cardiovascular risk prediction in cancer survivors - Takeaways - MDSpire

A risky business: recalibrating the future of cardiovascular risk prediction in cancer survivors

  • By

  • Lorcan Ruane

  • Sivatharshini Ramalingam

  • Alexander R Lyon

  • January 30, 2026

  • 0 min

Share

  • 1

    Cancer survivors face an increased risk of cardiovascular disease, which may surpass cancer-related mortality in some populations.

  • 2

    Traditional cardiovascular risk factors and cancer-specific variables contribute to elevated cardiovascular risk in cancer patients.

  • 3

    The SCORE2 CV risk prediction tool underestimates cardiovascular events in cancer patients, particularly in females.

  • 4

    Recalibration of existing risk tools may improve their predictive performance, but further validation in larger cohorts is necessary.

  • 5

    Significant heterogeneity in cardiovascular risk exists among cancer types and sexes, complicating risk assessment.

Original Source(s)

A risky business: recalibrating the future of cardiovascular risk prediction in cancer survivors

  • by Lorcan Ruane, Sivatharshini Ramalingam, Alexander R Lyon

  • January 30, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Case Report: Persistent fifth aortic arch with coarctation and fourth aortic arch interruption causing infant heart failure – the prenatal and postnatal echocardiographic course

An epidemiological assessment of the distribution and sociodemographic burden of chronic diseases: a focus on hypertension, diabetes, and cardiovascular conditions